#United States #New York #Fathom Therapeutics #MICROCOSMOS #Bret Williams

Fathom Therapeutics Strengthens Leadership with New Chief Scientific Officer

Fathom Therapeutics, a pioneering drug design firm, recently announced the appointment of Dr. Bret Williams as its Chief Scientific Officer. This strategic move comes as the company seeks to translate the insights derived from its unique Microcosmos platform into tangible therapeutic programs.

The Microcosmos platform utilizes cutting-edge quantum chemistry and artificial intelligence to predict how newly designed drug molecules will behave within living organisms. Dr. Williams will play a crucial role in steering the development of novel pharmaceutical candidates created using this advanced technology.

Dr. Williams, who brings over two decades of experience in drug discovery and translational research, is charged with advancing the company's ambitious mission following a notable $55 million Series A financing round completed in May 2026. This round was spearheaded by Sutter Hill Ventures and included participation from Lilly Ventures, demonstrating strong investor confidence in Fathom Therapeutics' innovative approach.

Fathom's Co-Founder and CEO, Dr. Huafeng Xu, expressed enthusiasm regarding Dr. Williams' appointment, stating that his deep understanding of the underlying science, along with his experience in applying AI to drug discovery, will significantly enhance the company's endeavors in translating groundbreaking scientific insights into effective medicines. Dr. Xu emphasized that Dr. Williams' expertise in navigating the transition from target identification to clinical development is an invaluable asset to the team.

Dr. Williams himself shared his excitement about joining Fathom Therapeutics, highlighting the pioneering work of the founding team in simulating protein-drug interactions. He remarked that the Microcosmos platform offers unparalleled accuracy in capturing protein dynamics, which can accelerate the discovery of highly potent drug candidates targeting previously considered undruggable diseases.

He elaborated on the implications of this technology, noting that the advanced understanding of protein behavior allows for the development of drugs that can precisely target specific proteins with significantly lower risks of off-target effects. With the completion of the initial design and simulation phases, Dr. Williams is eager to propel the most promising candidates into clinical studies, aiming to build a diverse portfolio of effective therapies.

Prior to joining Fathom Therapeutics, Dr. Williams held pivotal positions at Magnet Biomedicine, where he served as Senior Vice President and Head of Research, and Relay Therapeutics, where he spearheaded target identification and drug development initiatives. He also previously led a lab focused on molecular discovery at Sanofi. His extensive background encompasses crucial areas such as target identification, biomarker development, and the application of Machine Learning in precision medicine, particularly in treating oncology, autoimmune disorders, and rare diseases.

Dr. Williams earned his Ph.D. in cellular and molecular biology from the University of Wisconsin-Madison and completed a postdoctoral fellowship at MIT, showcasing a solid educational foundation to support his distinguished career.

Fathom Therapeutics is dedicated to redefining drug discovery through physics-based simulations that model protein dynamics at the atomic level. By leveraging these innovative methodologies within its Microcosmos platform, the company is well-positioned to design small molecules that demonstrate distinct therapeutic effects with reduced risks.

With this new appointment, Fathom Therapeutics is poised to increase its impact in the pharmaceutical space, translating rigorous scientific research into effective treatments that could change the lives of patients suffering from various ailments. Fathom Therapeutics, headquartered in New York, continues to lead the charge in the evolution of drug design and development.